O	O	0	10	Inhibition	Inhibition	B-NP	NN	O	0	ROOT	O
O	O	11	13	of	of	B-PP	IN	O	1	NMOD	O
O	O	14	17	HIV	HIV	B-NP	NN	O	6	NMOD	O
O	O	17	18	-	-	B-NP	HYPH	O	6	NMOD	O
O	O	18	19	1	1	I-NP	CD	O	6	NMOD	O
O	O	20	31	replication	replication	I-NP	NN	O	12	NMOD	O
O	O	32	35	and	and	I-NP	CC	O	12	NMOD	O
T5	B-Entity	36	38	NF	NF	I-NP	NN	B-protein	12	NMOD	B-protein
T5	I-Entity	38	39	-	-	B-NP	HYPH	I-protein	12	NMOD	I-protein
T5	I-Entity	39	44	kappa	kappa	I-NP	NN	I-protein	12	NMOD	I-protein
T5	I-Entity	45	46	B	B	I-NP	NN	I-protein	12	NMOD	I-protein
O	O	47	55	activity	activity	I-NP	NN	O	2	PMOD	O
O	O	56	58	by	by	B-PP	IN	O	1	NMOD	O
T6	B-Entity	59	67	cysteine	cysteine	B-NP	NN	O	17	NMOD	O
O	O	68	71	and	and	O	CC	O	17	NMOD	O
O	O	72	80	cysteine	cysteine	B-NP	NN	O	17	NMOD	O
O	O	81	92	derivatives	derivative	I-NP	NNS	O	13	PMOD	O
O	O	92	93	.	.	O	.	O	1	P	O

O	O	95	98	HIV	HIV	B-NP	NN	B-DNA	5	NMOD	B-DNA
O	O	98	99	-	-	B-NP	HYPH	I-DNA	5	NMOD	I-DNA
O	O	99	100	1	1	I-NP	CD	I-DNA	5	NMOD	I-DNA
O	O	101	109	proviral	proviral	I-NP	JJ	I-DNA	5	NMOD	I-DNA
O	O	110	113	DNA	DNA	I-NP	NN	I-DNA	6	SUB	I-DNA
O	O	114	122	contains	contain	B-VP	VBZ	O	0	ROOT	O
O	O	123	126	two	two	B-NP	CD	O	9	NMOD	O
T7	B-Entity	127	134	binding	bind	I-NP	VBG	B-DNA	9	NMOD	B-DNA
T7	I-Entity	135	140	sites	site	I-NP	NNS	I-DNA	6	OBJ	I-DNA
O	O	141	144	for	for	B-PP	IN	O	9	NMOD	O
O	O	145	148	the	the	B-NP	DT	O	17	NMOD	O
O	O	149	162	transcription	transcription	I-NP	NN	B-protein	13	NMOD	B-protein
O	O	163	169	factor	factor	I-NP	NN	I-protein	17	NMOD	I-protein
T8	B-Entity	170	172	NF	NF	I-NP	NN	B-protein	17	NMOD	B-protein
T8	I-Entity	172	173	-	-	B-NP	HYPH	I-protein	17	NMOD	I-protein
T8	I-Entity	173	178	kappa	kappa	I-NP	NN	I-protein	17	NMOD	I-protein
T8	I-Entity	179	180	B	B	I-NP	NN	I-protein	10	PMOD	I-protein
O	O	180	181	.	.	O	.	O	6	P	O

O	O	182	185	HIV	HIV	B-NP	NN	O	6	NMOD	O
O	O	185	186	-	-	B-NP	HYPH	O	1	P	O
O	O	186	187	1	1	I-NP	CD	O	1	NMOD	O
O	O	187	188	-	-	I-NP	HYPH	O	6	NMOD	O
O	O	188	196	infected	infected	I-NP	JJ	O	6	NMOD	O
O	O	197	208	individuals	individual	I-NP	NNS	O	7	SUB	O
O	O	209	213	have	have	B-VP	VBP	O	0	ROOT	O
O	O	213	214	,	,	O	,	O	7	P	O
O	O	215	217	on	on	B-PP	IN	O	7	VMOD	O
O	O	218	225	average	average	B-NP	NN	O	9	PMOD	O
O	O	225	226	,	,	O	,	O	7	P	O
O	O	227	237	abnormally	abnormally	B-NP	RB	O	13	AMOD	O
O	O	238	242	high	high	I-NP	JJ	O	14	NMOD	O
O	O	243	249	levels	level	I-NP	NNS	O	29	NMOD	O
O	O	250	252	of	of	B-PP	IN	O	14	NMOD	O
T1	B-Protein	253	259	tumour	tumour	B-NP	NN	B-protein	19	NMOD	B-protein
T1	I-Protein	260	268	necrosis	necrosis	I-NP	NN	I-protein	19	NMOD	I-protein
T1	I-Protein	269	275	factor	factor	I-NP	NN	I-protein	19	NMOD	I-protein
T1	I-Protein	276	281	alpha	alpha	I-NP	NN	I-protein	15	PMOD	I-protein
O	O	282	283	(	(	O	(	O	23	DEP	O
T2	B-Protein	283	286	TNF	TNF	B-NP	NN	B-protein	22	NMOD	B-protein
T2	I-Protein	287	292	alpha	alpha	I-NP	NN	I-protein	23	DEP	I-protein
O	O	292	293	)	)	O	)	O	19	NMOD	O
O	O	294	297	and	and	O	CC	O	29	NMOD	O
O	O	298	308	abnormally	abnormally	B-NP	RB	O	26	AMOD	O
O	O	309	312	low	low	I-NP	JJ	O	29	NMOD	O
O	O	313	319	plasma	plasma	I-NP	NN	O	29	NMOD	O
T9	B-Entity	320	328	cysteine	cysteine	I-NP	NN	O	29	NMOD	O
O	O	329	335	levels	level	I-NP	NNS	O	7	OBJ	O
O	O	335	336	.	.	O	.	O	7	P	O

O	O	337	339	We	We	B-NP	PRP	O	3	SUB	O
O	O	340	349	therefore	therefore	B-ADVP	RB	O	3	VMOD	O
O	O	350	362	investigated	investigate	B-VP	VBD	O	0	ROOT	O
O	O	363	366	the	the	B-NP	DT	O	5	NMOD	O
O	O	367	374	effects	effect	I-NP	NNS	O	3	OBJ	O
O	O	375	377	of	of	B-PP	IN	O	5	NMOD	O
T10	B-Entity	378	386	cysteine	cysteine	B-NP	NN	O	10	NMOD	O
O	O	387	390	and	and	O	CC	O	10	NMOD	O
O	O	391	398	related	related	B-NP	JJ	O	10	NMOD	O
O	O	399	405	thiols	thiol	I-NP	NNS	O	6	PMOD	O
O	O	406	408	on	on	B-PP	IN	O	5	NMOD	O
O	O	409	412	HIV	HIV	B-NP	NN	O	15	NMOD	O
O	O	412	413	-	-	B-NP	HYPH	O	15	NMOD	O
O	O	413	414	1	1	I-NP	CD	O	15	NMOD	O
O	O	415	426	replication	replication	I-NP	NN	O	21	NMOD	O
O	O	427	430	and	and	I-NP	CC	O	21	NMOD	O
T11	B-Entity	431	433	NF	NF	I-NP	NN	B-protein	21	NMOD	B-protein
T11	I-Entity	433	434	-	-	B-NP	HYPH	I-protein	21	NMOD	I-protein
T11	I-Entity	434	439	kappa	kappa	I-NP	NN	I-protein	21	NMOD	I-protein
T11	I-Entity	440	441	B	B	I-NP	NN	I-protein	21	NMOD	I-protein
O	O	442	452	expression	expression	I-NP	NN	O	11	PMOD	O
O	O	452	453	.	.	O	.	O	3	P	O

O	O	454	457	The	The	B-NP	DT	O	2	NMOD	O
O	O	458	469	experiments	experiment	I-NP	NNS	O	6	SUB	O
O	O	470	472	in	in	B-PP	IN	O	2	NMOD	O
O	O	473	477	this	this	B-NP	DT	O	5	NMOD	O
O	O	478	484	report	report	I-NP	NN	O	3	PMOD	O
O	O	485	489	show	show	B-VP	VBP	O	0	ROOT	O
O	O	490	494	that	that	B-SBAR	IN	O	6	VMOD	O
T12	B-Entity	495	503	cysteine	cysteine	B-NP	NN	O	10	NMOD	O
O	O	504	506	or	or	I-NP	CC	O	10	NMOD	O
T13	B-Entity	507	508	N	N	I-NP	NN	O	16	SUB	O
T13	I-Entity	508	509	-	-	O	HYPH	O	16	P	O
T13	I-Entity	509	523	acetylcysteine	acetylcysteine	B-NP	NN	O	16	SUB	O
O	O	524	525	(	(	O	(	O	15	DEP	O
T14	B-Entity	525	528	NAC	NAC	B-NP	NN	O	15	DEP	O
O	O	528	529	)	)	O	)	O	12	NMOD	O
O	O	530	535	raise	raise	B-VP	VBP	O	7	SBAR	O
O	O	536	539	the	the	B-NP	DT	O	23	NMOD	O
O	O	540	553	intracellular	intracellular	I-NP	JJ	O	23	NMOD	O
T15	B-Entity	554	565	glutathione	glutathione	I-NP	NN	O	23	NMOD	O
O	O	566	567	(	(	I-NP	(	O	23	NMOD	O
T16	B-Entity	567	570	GSH	GSH	I-NP	NN	O	23	NMOD	O
O	O	570	571	)	)	I-NP	)	O	23	NMOD	O
O	O	572	577	level	level	I-NP	NN	O	16	OBJ	O
O	O	578	581	and	and	O	CC	O	16	VMOD	O
O	O	582	589	inhibit	inhibit	B-VP	VBP	O	16	VMOD	O
O	O	590	593	HIV	HIV	B-NP	NN	O	29	NMOD	O
O	O	593	594	-	-	B-NP	HYPH	O	29	NMOD	O
O	O	594	595	1	1	I-NP	CD	O	29	NMOD	O
O	O	596	607	replication	replication	I-NP	NN	O	25	OBJ	O
O	O	608	610	in	in	B-PP	IN	O	29	NMOD	O
O	O	611	623	persistently	persistently	B-NP	RB	O	32	AMOD	O
O	O	624	632	infected	infected	I-NP	JJ	O	38	NMOD	O
O	O	633	637	Molt	Molt	I-NP	NNP	O	38	NMOD	O
O	O	637	638	-	-	O	:	O	38	P	O
O	O	638	639	4	4	B-NP	CD	O	38	NMOD	O
O	O	640	643	and	and	I-NP	CC	O	38	NMOD	O
O	O	644	648	U937	U937	I-NP	NN	B-cell_line	38	NMOD	B-cell_line
O	O	649	654	cells	cell	I-NP	NNS	I-cell_line	30	PMOD	I-cell_line
O	O	654	655	.	.	O	.	O	6	P	O

O	O	656	663	However	However	B-ADVP	RB	O	9	VMOD	O
O	O	663	664	,	,	O	,	O	9	P	O
O	O	665	675	inhibition	inhibition	B-NP	NN	O	9	SUB	O
O	O	676	678	of	of	B-PP	IN	O	3	NMOD	O
O	O	679	682	HIV	HIV	B-NP	NN	O	8	NMOD	O
O	O	682	683	-	-	B-NP	HYPH	O	8	NMOD	O
O	O	683	684	1	1	I-NP	CD	O	8	NMOD	O
O	O	685	696	replication	replication	I-NP	NN	O	4	PMOD	O
O	O	697	704	appears	appear	B-VP	VBZ	O	0	ROOT	O
O	O	705	708	not	not	O	RB	O	12	VMOD	O
O	O	709	711	to	to	B-VP	TO	O	12	VMOD	O
O	O	712	714	be	be	I-VP	VB	O	9	VMOD	O
O	O	715	723	directly	directly	I-VP	RB	O	12	VMOD	O
O	O	724	734	correlated	correlate	I-VP	VBN	O	12	VC	O
O	O	735	739	with	with	B-PP	IN	O	14	VMOD	O
T17	B-Entity	740	743	GSH	GSH	B-NP	NN	O	17	NMOD	O
O	O	744	750	levels	level	I-NP	NNS	O	15	PMOD	O
O	O	750	751	.	.	O	.	O	9	P	O

T18	B-Entity	752	760	Cysteine	Cysteine	B-NP	NN	O	3	NMOD	O
O	O	761	764	and	and	I-NP	CC	O	3	NMOD	O
T19	B-Entity	765	768	NAC	NAC	I-NP	NN	O	5	SUB	O
O	O	769	773	also	also	B-ADVP	RB	O	5	VMOD	O
O	O	774	781	inhibit	inhibit	B-VP	VBP	O	0	ROOT	O
T20	B-Entity	782	784	NF	NF	B-NP	NN	B-protein	10	NMOD	B-protein
T20	I-Entity	784	785	-	-	B-NP	HYPH	I-protein	10	P	I-protein
T20	I-Entity	785	790	kappa	kappa	I-NP	NN	I-protein	10	NMOD	I-protein
T20	I-Entity	791	792	B	B	I-NP	NN	I-protein	10	NMOD	I-protein
O	O	793	801	activity	activity	I-NP	NN	O	5	OBJ	O
O	O	802	804	as	as	B-SBAR	IN	O	10	NMOD	O
O	O	805	815	determined	determine	B-VP	VBN	O	11	SBAR	O
O	O	816	818	by	by	B-PP	IN	O	12	VMOD	O
O	O	819	834	electrophoretic	electrophoretic	B-NP	JJ	O	17	NMOD	O
O	O	835	843	mobility	mobility	I-NP	NN	O	17	NMOD	O
O	O	844	849	shift	shift	I-NP	NN	O	17	NMOD	O
O	O	850	856	assays	assay	I-NP	NNS	O	27	NMOD	O
O	O	857	860	and	and	O	CC	O	22	NMOD	O
T3	B-Protein	861	876	chloramphenicol	chloramphenicol	B-NP	NN	B-protein	22	NMOD	B-protein
T3	I-Protein	877	883	acetyl	acetyl	I-NP	NN	I-protein	22	NMOD	I-protein
T3	I-Protein	883	884	-	-	O	HYPH	I-protein	22	P	I-protein
T3	I-Protein	884	895	transferase	transferase	B-NP	NN	I-protein	27	NMOD	I-protein
O	O	896	897	(	(	O	(	O	25	DEP	O
T4	B-Protein	897	900	CAT	CAT	B-NP	NN	O	25	DEP	O
O	O	900	901	)	)	O	)	O	22	NMOD	O
O	O	902	906	gene	gene	B-NP	NN	O	27	NMOD	O
O	O	907	917	expression	expression	I-NP	NN	O	13	PMOD	O
O	O	918	923	under	under	B-PP	IN	O	27	NMOD	O
O	O	924	931	control	control	B-NP	NN	O	28	PMOD	O
O	O	932	934	of	of	B-PP	IN	O	29	NMOD	O
T21,T22	B-Entity,B-Entity	935	937	NF	NF	B-NP	NN	B-DNA	36	NMOD	B-DNA
T21,T22	I-Entity,I-Entity	937	938	-	-	B-NP	HYPH	I-DNA	36	NMOD	I-DNA
T21,T22	I-Entity,I-Entity	938	943	kappa	kappa	I-NP	NN	I-DNA	36	NMOD	I-DNA
T21,T22	I-Entity,I-Entity	944	945	B	B	I-NP	NN	I-DNA	36	NMOD	I-DNA
T21	I-Entity	946	953	binding	binding	I-NP	NN	I-DNA	36	NMOD	I-DNA
T21	I-Entity	954	959	sites	site	I-NP	NNS	I-DNA	30	PMOD	I-DNA
O	O	960	962	in	in	B-PP	IN	O	36	NMOD	O
O	O	963	973	uninfected	uninfected	B-NP	JJ	B-cell_type	39	NMOD	B-cell_type
O	O	974	979	cells	cell	I-NP	NNS	I-cell_type	37	PMOD	I-cell_type
O	O	979	980	.	.	O	.	O	5	P	O

O	O	981	985	This	This	B-NP	DT	O	2	SUB	O
O	O	986	994	suggests	suggest	B-VP	VBZ	O	0	ROOT	O
O	O	995	999	that	that	B-SBAR	IN	O	2	VMOD	O
O	O	1000	1003	the	the	B-NP	DT	O	6	NMOD	O
T23	B-Entity	1004	1012	cysteine	cysteine	I-NP	NN	O	6	NMOD	O
O	O	1013	1023	deficiency	deficiency	I-NP	NN	O	14	SUB	O
O	O	1024	1026	in	in	B-PP	IN	O	6	NMOD	O
O	O	1027	1030	HIV	HIV	B-NP	NN	O	13	NMOD	O
O	O	1030	1031	-	-	B-NP	HYPH	O	13	NMOD	O
O	O	1031	1032	1	1	I-NP	CD	O	13	NMOD	O
O	O	1032	1033	-	-	I-NP	HYPH	O	12	AMOD	O
O	O	1033	1041	infected	infect	I-NP	VBN	O	13	NMOD	O
O	O	1042	1053	individuals	individual	I-NP	NNS	O	7	PMOD	O
O	O	1054	1057	may	may	B-VP	MD	O	3	SBAR	O
O	O	1058	1063	cause	cause	I-VP	VB	O	14	VC	O
O	O	1064	1066	an	an	B-NP	DT	O	15	OBJ	O
O	O	1067	1071	over	over	I-NP	AFX	O	16	SBAR	O
O	O	1071	1072	-	-	I-NP	HYPH	O	17	OBJ	O
O	O	1072	1082	expression	expression	I-NP	NN	O	18	OBJ	O
O	O	1083	1085	of	of	B-PP	IN	O	19	NMOD	O
T24,T25	B-Entity,B-Entity	1086	1088	NF	NF	B-NP	NN	B-protein	24	NMOD	B-protein
T24,T25	I-Entity,I-Entity	1088	1089	-	-	B-NP	HYPH	I-protein	24	NMOD	I-protein
T24,T25	I-Entity,I-Entity	1089	1094	kappa	kappa	I-NP	NN	I-protein	24	NMOD	I-protein
T24,T25	I-Entity,I-Entity	1095	1096	B	B	I-NP	NN	I-protein	27	NMOD	I-protein
T24	I-Entity	1096	1097	-	-	B-NP	HYPH	O	27	NMOD	O
T24	I-Entity	1097	1106	dependent	dependent	I-NP	JJ	O	27	NMOD	O
T24	I-Entity	1107	1112	genes	gene	I-NP	NNS	O	20	PMOD	O
O	O	1113	1116	and	and	O	CC	O	17	VMOD	O
O	O	1117	1124	enhance	enhance	B-VP	VBP	O	17	VMOD	O
O	O	1125	1128	HIV	HIV	B-NP	NN	O	33	NMOD	O
O	O	1128	1129	-	-	B-NP	HYPH	O	33	NMOD	O
O	O	1129	1130	1	1	I-NP	CD	O	33	NMOD	O
O	O	1131	1142	replication	replication	I-NP	NN	O	29	OBJ	O
O	O	1142	1143	.	.	O	.	O	2	P	O

T26	B-Entity	1144	1147	NAC	NAC	B-NP	NN	O	2	SUB	O
O	O	1148	1151	may	may	B-VP	MD	O	0	ROOT	O
O	O	1152	1154	be	be	I-VP	VB	O	2	VC	O
O	O	1155	1165	considered	consider	I-VP	VBN	O	3	VC	O
O	O	1166	1169	for	for	B-PP	IN	O	4	VMOD	O
O	O	1170	1173	the	the	B-NP	DT	O	7	NMOD	O
O	O	1174	1183	treatment	treatment	I-NP	NN	O	5	PMOD	O
O	O	1184	1186	of	of	B-PP	IN	O	7	NMOD	O
O	O	1187	1190	HIV	HIV	B-NP	NN	O	14	NMOD	O
O	O	1190	1191	-	-	B-NP	HYPH	O	14	P	O
O	O	1191	1192	1	1	I-NP	CD	O	14	NMOD	O
O	O	1192	1193	-	-	I-NP	HYPH	O	14	NMOD	O
O	O	1193	1201	infected	infect	I-NP	VBN	O	14	NMOD	O
O	O	1202	1213	individuals	individual	I-NP	NNS	O	8	PMOD	O
O	O	1213	1214	.	.	O	.	O	2	P	O
